To all ROS1+ non-small cell lung cancer (NSCLC) patients in the United Kingdom (UK):
Please help advocate for coverage of crizotinib (Xalkori) for ROS1+ NSCLC through the UK’s national health system. The Roy Castle Lung Cancer Foundation is putting together a submission on behalf of ROS1+ patients, and they are looking for patient experience quotes, preferably from the UK. They do not need personal details.
If you are interested in sharing your ROS1+ patient experience, please contact
Nicola Forrest (Support Services Manager for Roy Castle Lung Cancer Foundation) by one of the methods below:
- email: email@example.com
- phone: 0800 358 7200
- private message on Health Unlocked’s Roy Castle Lung Cancer Foundation community
She will get in touch with you after Thursday February 15.
Thanks for your help!